EUVIMEDEUVIMED entdecken
Crossref

Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer

Hikari Chidimatsu, Ryouichi Tsunedomi, Yuki Nakagami, Ming Xu, Masao Nakajima, Chiyo Nakashima-Nakasuga, Shinobu Tomochika, Shin Yoshida, Nobuaki Suzuki, Yusaku Watanabe, Hiroto Matsui, Yoshitaro Shindo und 9 weitere

Anticancer Research · 2023

DOI: 10.21873/anticanres.16139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Hikari Chidimatsu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. Hauptthemen laut MEDLINE: Chemokine CCL7, Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Colorectal cancer is the third most common cancer globally, and the poor prognosis of patients with metastatic colorectal cancer (mCRC) warrants urgent attention. We previously obtained 10 candidate serum biomarkers for mCRC. Our aim with this study was to determine the prognostic performance of the pre-treatment serum C-C motif chemokine ligand 7 (CCL7) concentration in patients with mCRC. PATIENTS AND METHODS: Protein concentrations of CCL7 were examined using ELISA and immunohistochemistry for serum (n=110) and surgical specimens (n=85), respectively, of patients with mCRC. The relationship between protein concentration and prognosis was examined using Cox regression analysis, receiver operator characteristic curve analysis and the Kaplan-Meier method. RESULTS: The overall survival (OS) of patients with high concentrations of serum CCL7 was significantly poorer than that of patients with low concentrations. Patients with a high CCL7 concentration in the stroma had significantly poorer outcomes than those with a low concentration. The concentrations of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 were significantly higher in the high-CCL7 group, compared to those in the low-CCL7 group. Univariate and multivariate analysis revealed that serum CCL7 concentration was a significant prognostic factor for mCRC. The combination of serum CCL and CEA concentrations was also useful in this regard (area under the curve=0.71). CONCLUSION: The combined pre-treatment serum levels of CCL7 and CEA are useful prognostic biomarkers for mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CCL7Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsHumansBiomarkers, TumorCarcinoembryonic AntigenLigandsPrognosisRetrospective Studies

Stichwörter der Autor:innen

BiomarkerCCL7metastatic colorectal cancerprognosisserum

Substanzen

Biomarkers, TumorCarcinoembryonic AntigenCCL7 protein, humanChemokine CCL7Ligands

Autor:innen und Institutionen

  • Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Department of Public Health and Preventive Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Oncology Center, Yamaguchi University Hospital, Yamaguchi, Japan.
  • Department of Gastroenterological Surgery, Kawasaki Medical School, Okayama, Japan.
  • Department of Diagnostic Pathology, Yamaguchi University Hospital, Yamaguchi, Japan.
  • Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan; hnagano@yamaguchi-u.ac.jp.

Zitieren

APA

Chidimatsu, H., Tsunedomi, R., Nakagami, Y., Xu, M., Nakajima, M., Nakashima-Nakasuga, C., Tomochika, S., Yoshida, S., Suzuki, N., Watanabe, Y., Matsui, H., Shindo, Y., Tokumitsu, Y., Iida, M., Takeda, S., Ioka, T., Ueno, T., Tanabe, T., Hoshii, Y., …, & Nagano, H. (2023). Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16139

Vancouver

Chidimatsu H, Tsunedomi R, Nakagami Y, Xu M, Nakajima M, Nakashima-Nakasuga C, et al. Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16139

BibTeX
@article{Chidimatsu2023,
  author = {Chidimatsu, Hikari and Tsunedomi, Ryouichi and Nakagami, Yuki and Xu, Ming and Nakajima, Masao and Nakashima-Nakasuga, Chiyo and Tomochika, Shinobu and Yoshida, Shin and Suzuki, Nobuaki and Watanabe, Yusaku and Matsui, Hiroto and Shindo, Yoshitaro and Tokumitsu, Yukio and Iida, Michihisa and Takeda, Shigeru and Ioka, Tatsuya and Ueno, Tomio and Tanabe, Tsuyoshi and Hoshii, Yoshinobu and Hazama, Shoichi and Nagano, Hiroaki},
  title = {Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16139}
}
Kostenlos starten →